GlassScriptPhysician profile
Charles J Kaiser
NPI 1801859962
$15,518.50
in general payments reported to CMS, 2019-2025
41 companies · $3,576 in 2025
The $3,576 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $1,034 · 2021: $1,374 · 2022: $2,227 · 2023: $3,125 · 2024: $3,418 · 2025: $3,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $3.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,114.63 |
| Education | $3.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,185.21 | 2019-2025 | Simbrinza, Clareon, Rhopressa |
| Bausch & Lomb Americas INC. | $1,349.29 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| New World Medical,INC. | $1,308.71 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Abbvie INC. | $1,007.32 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $927.56 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $890.04 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $845.15 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $821.99 | 2019-2025 | Cequa |
| Allergan, INC. | $821.21 | 2019-2022 | |
| Biotissue Holdings INC. | $533.09 | 2020-2025 | |
| Rayner Intraocular Lenses Limited | $502.04 | 2023-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Harrow Eye, LLC | $478.08 | 2024-2025 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $381.47 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $342.26 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $335.35 | 2023-2025 | Syfovre |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $327.90 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $291.19 | 2019-2021 | |
| Astellas Pharma US INC | $267.32 | 2024-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $245.53 | 2019-2021 | |
| Sight Sciences, INC. | $212.63 | 2022-2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $173.81 | 2021-2025 | Eylea Hd, Eylea |
| Thea Pharma INC. | $171.26 | 2024-2025 | Iyuzeh |
| Horizon Therapeutics Plc | $170.99 | 2019-2023 | Tepezza |
| Genentech USA, INC. | $136.67 | 2024-2025 | Vabysmo |
| Merz Pharmaceuticals, LLC | $121.69 | 2022-2025 | Xeomin |
| Ani Pharmaceuticals, INC. | $104.92 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Halozyme INC | $70.92 | 2024-2025 | Hylenex Recombinant |
| Rxsight INC | $62.03 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $51.89 | 2020-2021 | |
| Beaver-Visitec International, INC. | $47.76 | 2020 | |
| Dompe US, INC. | $46.41 | 2021-2022 | |
| Coherus Oncology, INC. | $43.64 | 2023 | |
| Glaukos Corporation | $39.28 | 2024 | Ce-Marked Kxla System |
| Alimera Sciences, INC. | $35.57 | 2022 | |
| Iridex Corporation | $35.03 | 2019-2021 | |
| Immunocore Limited | $30.33 | 2023 | Kimmtrak |
| Mallinckrodt Enterprises LLC | $27.82 | 2019 | |
| Amgen INC. | $21.54 | 2025 | Tepezza |
| Omeros Corporation | $19.83 | 2020 | |
| Kedrion Biopharma, INC. | $16.94 | 2024 | Gammaked, Koate, Albuked |
| Carl Zeiss Meditec, INC. | $16.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.